Evidence method
Level · gp.fundamentals.debt_to_revenue
72.50% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
ANIP · Dec 31, 2017
ANI PHARMACEUTICALS INC. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001144204-18-011197General Corporate
Evidence method
Level · gp.fundamentals.capex_revenue_ratio
5.86% · OPTIONAL · VALID
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
22.29% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
37.49% · CORE · VALID
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
21.33% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.gross_margin
55.31% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
16.02% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
5.13% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
3.44% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History49 statesSelf-history eligible
Sep 30, 20218/8 normalizedLevel 3Dec 31, 20218/8 normalizedLevel 3Mar 31, 20228/8 normalizedLevel 3Jun 30, 20228/8 normalizedLevel 3Sep 30, 20228/8 normalizedLevel 3Dec 31, 20228/8 normalizedLevel 3Mar 31, 20238/8 normalizedLevel 3Jun 30, 20238/8 normalizedLevel 3Sep 30, 20238/8 normalizedLevel 3Dec 31, 20238/8 normalizedLevel 3Mar 31, 20248/8 normalizedLevel 3Jun 30, 20248/8 normalizedLevel 3Sep 30, 20248/8 normalizedLevel 3Dec 31, 20248/8 normalizedLevel 3Mar 31, 20258/8 normalizedLevel 3Jun 30, 20258/8 normalizedLevel 3Sep 30, 20258/8 normalizedLevel 3Dec 31, 20258/8 normalizedLevel 3Mar 31, 20268/8 normalizedLevel 3Jun 30, 20268/8 normalizedLevel 4
Period transition
What moved in the state?
- Previous
- 262.20%
- Current
- 72.50%
- Delta
- -189.70%
- Previous
- 5.15%
- Current
- 5.86%
- Delta
- 0.71%
- Previous
- 35.47%
- Current
- 22.29%
- Delta
- -13.18%
- Previous
- 25.02%
- Current
- 37.49%
- Delta
- 12.47%
- Previous
- 79.89%
- Current
- 21.33%
- Delta
- -58.56%
- Previous
- 56.24%
- Current
- 55.31%
- Delta
- -0.93%
- Previous
- 19.37%
- Current
- 16.02%
- Delta
- -3.35%
- Previous
- 5.47%
- Current
- 5.13%
- Delta
- -0.34%
- Previous
- 3.04%
- Current
- 3.44%
- Delta
- 0.41%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · ANIP Fundamental State →Has State · ANI PHARMACEUTICALS INC →Transitioned To · ANIP Fundamental State →Transitioned To · ANIP BALANCE_SHEET_LEVERAGE_DECREASED →Transitioned To · ANIP CAPEX_INTENSITY_INCREASED →Transitioned To · ANIP CASH_GENERATION_DECREASED →Transitioned To · ANIP GROWTH_INCREASED →Transitioned To · ANIP INVENTORY_PRESSURE_DECREASED →Transitioned To · ANIP MARGIN_DECREASED →Transitioned To · ANIP PROFITABILITY_DECREASED →Transitioned To · ANIP R_AND_D_INTENSITY_DECREASED →Transitioned To · ANIP SBC_INTENSITY_INCREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.